Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market.

But they also won't be alone. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.

On May 3, the FDA approved the first vaccine targeting RSV for people 60 and over. GSK (NYSE: GSK) -- formerly known as GlaxoSmithKline -- is the maker of the vaccine, Arexvy, which has been highly effective in trials. It was 94.1% effective in lowering the risk of severe illnesses, and overall efficacy was 82.6%.

Continue reading

Source Fool.com